Medical illustration of the brain with a magnified cerebral capillary showing endothelial cells, tight junctions, astrocyte processes and a pericyte forming the blood-brain barrier.

The Blood-Brain Barrier: How Does the Brain Control What Gets In?

A patient arrives on the ward with suspected meningitis. They are febrile, photophobic and becoming increasingly drowsy. Their blood is circulating normally, carrying oxygen, glucose, medicines, immune cells and thousands of other substances. Yet blood reaching the brain does not have unrestricted access to brain tissue.

The reason is the blood-brain barrier (BBB). The name can make it sound as though the brain is wrapped in a separate protective wall. It is not. Much of the barrier is created within the walls of the tiny blood vessels running through the central nervous system, particularly the cerebral capillaries.

That arrangement creates an interesting problem. The brain cannot be isolated from the circulation because neurons have a continuous demand for oxygen and glucose. Carbon dioxide and other waste products also need to leave. At the same time, neural tissue is highly sensitive to changes in its chemical environment. The BBB allows the brain to remain supplied by blood while tightly regulating much of the exchange between that blood and the surrounding nervous tissue.

So what actually forms the blood-brain barrier?

Start with a cerebral capillary. Like capillaries elsewhere in the body, it is lined by endothelial cells. These cells form the interface between the blood inside the vessel and the tissue outside it. In the brain, however, the endothelial lining has several specialised features.

Neighbouring brain endothelial cells are joined by tight junctions. Proteins including claudins, occludin and junctional adhesion molecules help create these junctional complexes. In many peripheral capillaries, substances can move more freely through gaps or pathways between endothelial cells. At the BBB, movement through this paracellular route is greatly restricted. A substance in the blood therefore cannot simply assume that the space between two endothelial cells is an easy route into the brain.

The endothelial cells themselves are also unusual. They have relatively low levels of non-selective vesicular transport, or transcytosis, compared with many peripheral endothelial cells. They express specialised transport proteins and efflux systems that help determine what enters, what leaves and what may be transported back towards the bloodstream. Daneman and Prat (2015) describe these endothelial characteristics as central to the structure and function of the BBB.

The barrier is therefore selective rather than simply sealed. Small lipid-soluble molecules such as oxygen and carbon dioxide can diffuse through cell membranes relatively readily. Other substances depend on transport proteins. Glucose is a good example. Neurons rely heavily on glucose metabolism, but glucose does not simply diffuse across the BBB in sufficient quantities. Transport across brain endothelium occurs predominantly through GLUT1 glucose transporters. Amino acids, ions and other nutrients have their own regulated routes.

Some larger molecules can cross through receptor-mediated or adsorptive transport pathways, but these processes are selective. At the same time, ATP-binding cassette efflux transporters, including P-glycoprotein, can reduce the accumulation of certain substances within the brain by transporting them from endothelial cells back towards the blood. Whether a molecule reaches neural tissue therefore depends on more than its presence in the circulation.

The endothelial cells are only one part of the system. Pericytes are closely associated with the capillary wall and contribute to vascular stability and BBB properties. A basement membrane provides structural support. Astrocytes, a type of glial cell, extend end-feet around much of the cerebral microvasculature and participate in signalling between neural tissue and blood vessels. Neurons, microglia and vascular cells also interact locally.

Together these components are often described as the neurovascular unit. It is a better way of picturing the BBB than imagining a rigid wall. Blood flow, neuronal activity, endothelial behaviour and surrounding glial cells are closely connected. Friedman and colleagues (2025) describe the healthy BBB as dynamically regulated, with changes in barrier properties forming part of normal neurovascular physiology rather than the barrier existing in one permanently fixed state.

There are also regions of the brain where vascular interfaces differ from the classic BBB arrangement. Circumventricular organs, for example, need greater communication with circulating signals for functions such as endocrine regulation and sensing the composition of the blood. So even within the central nervous system, the phrase ‘the blood-brain barrier’ describes a specialised biological system rather than one identical physical structure surrounding every part of the brain.

What does this mean for medicines and disease?

Imagine a medicine has been given intravenously. It enters the circulation quickly and may achieve a measurable plasma concentration. That still does not tell you how much active drug reaches the brain.

Movement into the central nervous system can be influenced by molecular size, lipid solubility, electrical charge, protein binding, concentration gradients and whether suitable transport pathways exist. Efflux transporters may further reduce drug accumulation. A medicine can therefore circulate successfully around the body while penetrating brain tissue poorly.

This creates a major problem in neurological therapeutics. A drug may have an appropriate biological target inside the brain but still be of limited use if it cannot reach that target in an effective concentration. Researchers have explored approaches including altering drug properties, using carrier or receptor-mediated transport, temporarily modifying barrier permeability and delivering treatment more directly. In glioblastoma, for example, the BBB and the altered blood-tumour barrier can complicate effective delivery of anticancer treatment. Mokarram and colleagues (2025) review device-assisted approaches being investigated to improve drug delivery across these barriers.

For nursing pharmacology, the useful distinction is between a drug being in the bloodstream and a drug reaching an effective concentration at its site of action in the central nervous system. The BBB helps explain why those are not automatically the same thing.

The barrier can also change during disease. Return to the patient with suspected meningitis. Bacterial meningitis produces inflammation in the meninges and a wider inflammatory response within the central nervous system. Inflammatory mediators can affect cerebral endothelial cells, tight-junction integrity and other components of the neurovascular unit. Barrier permeability may increase and the carefully regulated movement of cells, proteins and fluid can become disturbed.

It is tempting to describe this as the BBB simply ‘opening’, but that picture is too crude. Different transport pathways and junctional mechanisms can be altered to different degrees, and the changes occur alongside inflammation, vascular dysfunction and altered fluid handling. Increased permeability can contribute to cerebral oedema and secondary neurological injury rather than acting as a useful doorway that has merely been unlocked.

BBB dysfunction is also associated with stroke and traumatic brain injury, where vascular and inflammatory injury can disrupt endothelial function. It is increasingly studied in neurodegenerative disorders, where changes in barrier integrity, transport and neurovascular signalling may interact with the disease process. Searson and Banks (2026) review the growing evidence around BBB dysfunction and therapeutic strategies aimed at barrier rejuvenation and repair.

The relationship between disease and the BBB can run in both directions. A neurological insult may damage barrier function, while altered barrier function can then change the environment around neurons and contribute to further injury. That is one reason the BBB is better understood as part of the physiology of the neurovascular unit rather than as a passive sheet of cells.

Back at the bedside

A nurse does not measure BBB permeability during a routine neurological assessment. What you see is the patient and the clinical consequences of the process affecting their brain.

For the patient with suspected meningitis, increasing drowsiness, a falling Glasgow Coma Scale score, seizures, focal neurological changes, severe headache or other deterioration require urgent assessment and escalation. The BBB helps explain part of the underlying physiology, but it does not replace the clinical priorities in front of you.

NICE guideline NG240 treats suspected bacterial meningitis as a medical emergency. In hospital, intravenous antibiotics should be given within one hour of arrival when bacterial meningitis is suspected. Investigations should be performed before antibiotics when it is safe to do so and when they will not cause a clinically significant delay. Lumbar puncture and neuroimaging decisions depend on the patient’s presentation and potential contraindications, so the sequence is not simply ‘scan everyone, then perform a lumbar puncture’. Nurses need to recognise deterioration, support timely investigations and treatment, and follow the national guidance relevant to their part of the UK alongside local antimicrobial and escalation policies.

The same physiology can help make sense of medicines used in neurological care. When you read that a medicine has poor central nervous system penetration, think back to the capillary. It may need to cross an endothelial cell membrane, use a transporter, avoid being pumped back into the blood and then reach enough brain tissue to produce an effect. ‘It does not cross the BBB’ is often a shorthand description of a much more complicated pharmacokinetic problem.

It also explains why the BBB cannot simply be made maximally permeable. Neural tissue depends on a controlled extracellular environment. Losing that selectivity can expose the brain to circulating molecules, inflammatory signals and fluid shifts that would normally be restricted. Protection and access have to exist at the same time.

So when you come across the blood-brain barrier in anatomy, pharmacology or neurological nursing, picture the cerebral microvessel rather than a wall around the brain. Endothelial cells form tight junctions. Transporters move essential nutrients such as glucose. Efflux systems restrict some substances. Pericytes and astrocytes help maintain the local vascular environment. Disease can disturb the system, and treatment may be limited by it.

Then the phrase ‘crossing the blood-brain barrier’ becomes a physiology question: what route would this substance need to use, and what is regulating that route?

References

Back to blog